buyModerate cluster of 5
Peter Feinberg bought $63k of IMRX
director at Immuneering Corp. 25,000 shares at an average of $2.53, traded Jun 18, 2025, filed Jun 23, 2025.
Conviction score
44Value
$63k
25,000 shares
Holdings after
136,766
+22% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +8Trade size$63k at market
- +6Relative to holdingsHoldings up 22%
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001790340-25-000083, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 18, 2025 | POpen-market purchase Class A Common Stock | +25,000 | $2.53 | $63k | 136,766 | Jun 23, 2025 |
Related signals
Other insiders at Immuneering Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 47Moderate | Immuneering Corp | Thomas J. Schall director | $35k 9,500 shares | +22% | |
| 36Weak | Immuneering Corp | Harold Eugene Brakewood Chief Business Officer | $4,804 1,900 shares | +49% | |
| 36Weak | Immuneering Corp | Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | $35k 13,422 shares | +4% | |
| 42Moderate | Immuneering Corp | Benjamin J. Zeskind PRESIDENT AND CEO | $50k 21,000 shares | +1% | |
| 49Moderate | Immuneering Corp | Thomas J. Schall director | $89k 40,485 shares | +1396% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.